Cargando…

Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts

Intestinal fibrosis is a common complication of inflammatory bowel disease. So far, there is no safe and effective drug for intestinal fibrosis. Pirfenidone is an anti-fibrotic compound available for the treatment of idiopathic pulmonary fibrosis. Here, we explored the anti-proliferative and anti-fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Yingying, Zhang, Mengfan, Leng, Changsen, Blokzijl, Tjasso, Jansen, Bernadien H., Dijkstra, Gerard, Faber, Klaas Nico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140656/ https://www.ncbi.nlm.nih.gov/pubmed/32235767 http://dx.doi.org/10.3390/cells9030775

Ejemplares similares

HIF1α-Dependent Induction of TFRC by a Combination of Intestinal Inflammation and Systemic Iron Deficiency in Inflammatory Bowel Disease
por: Fagundes, Raphael R., et al.
Publicado: (2022)

Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab
por: Trentadue, Guido, et al.
Publicado: (2020)

Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
por: van Haaften, Wouter Tobias, et al.
Publicado: (2020)

A simple coculture system shows mutualism between anaerobic faecalibacteria and epithelial Caco-2 cells
por: Sadaghian Sadabad, Mehdi, et al.
Publicado: (2015)

Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease
por: Hu, Shixian, et al.
Publicado: (2021)

Inulin-grown Faecalibacterium prausnitzii cross-feeds fructose to the human intestinal epithelium
por: Fagundes, Raphael R., et al.
Publicado: (2021)

Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease
por: Gabriëls, Ruben Y., et al.
Publicado: (2022)

A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2019)

In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion
por: Shi, Qiang, et al.
Publicado: (2011)

cGAS-STING signaling pathway in intestinal homeostasis and diseases
por: Yang, Yuchen, et al.
Publicado: (2023)

Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
por: Alexdottir, Marta S., et al.
Publicado: (2022)

A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment
por: Cui, Yingying, et al.
Publicado: (2023)

Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
por: von Martels, Julius Z. H., et al.
Publicado: (2019)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
por: Latella, Giovanni, et al.
Publicado: (2020)

Luminal Preservation Protects the Small Intestine in a Brain-dead Rat Model
por: Trentadue, Guido, et al.
Publicado: (2022)

Mesoporous Polydopamine Loaded Pirfenidone Target to Fibroblast Activation Protein for Pulmonary Fibrosis Therapy
por: Fang, Qi, et al.
Publicado: (2022)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues
por: Meyer, Friederike Elisabeth Ugi, et al.
Publicado: (2023)

SPARC and the N-propeptide of collagen I influence fibroblast proliferation and collagen assembly in the periodontal ligament
por: Rosset, Emilie Moore, et al.
Publicado: (2017)

Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
por: Bourgonje, Arno R., et al.
Publicado: (2023)

Pirfenidone suppresses TGF-β1-induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K/AKT signaling pathway
por: Sun, Yanwu, et al.
Publicado: (2018)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
por: Geng, Yana, et al.
Publicado: (2021)

The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro
por: Stougaard, Julie, et al.
Publicado: (2018)

Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis
por: Landskron, Glauben, et al.
Publicado: (2022)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Growth differentiation factor 7 autocrine signaling promotes hepatic progenitor cell expansion in liver fibrosis
por: Kong, Defu, et al.
Publicado: (2023)

Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts
por: Toda, Michihito, et al.
Publicado: (2018)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
por: Stahnke, Thomas, et al.
Publicado: (2017)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Effects of Pirfenidone and Collagen-Polyvinylpyrrolidone on Macroscopic and Microscopic Changes, TGF-β1 Expression, and Collagen Deposition in an Experimental Model of Tracheal Wound Healing
por: Olmos-Zuñiga, J. Raúl, et al.
Publicado: (2017)

Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Comparison of Attachment and Proliferation of Human Gingival Fibroblasts on Different Collagen Membranes
por: Talebi Ardakani, Mohammad Reza, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gcupmkat5gen8gafpkdtabg235